Richard Mason

Chief Executive Officer
Apollo Therapeutics

Dr Richard Mason is Apollo Therapeutics’ Chief Executive Officer. Richard has over 25 years’ experience in the biopharmaceutical industry, including leading Johnson & Johnson Innovation in Europe. Before this, he was CEO of novel anticoagulant antibody company XO1 until the company was acquired by Johnson & Johnson in March 2015. Previously, Richard was the executive leadership team member responsible for strategy and business development at listed companies BTG Plc and Cambridge Antibody Technology Plc where he led numerous M&A and partnering transactions. Richard has degrees in medicine from St. Bartholomew’s Hospital Medical College and immunology from University College London and trained in internal medicine in London. He has an MBA from the University of Cambridge. During 2020, he served on active military duty with the British Army as part of the UK government’s pandemic response, including as a member of the UK Vaccines Task Force. He is a Fellow of the Royal College of Physicians and an Honorary Fellow in both the Operations and Technology Management Group and the Cambridge Centre for Health Leadership and Enterprise at the Judge Business School, University of Cambridge.